$0.00
(Market cap
$13 Mln
Revenue (TTM)
$15 Mln
P/E Ratio
--
P/B Ratio
0.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-54 Mln
-
ROE
-1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.2
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
29,491,100
5 Years Aggregate
CFO
$-221.23 Mln
EBITDA
$-203.11 Mln
Net Profit
$-248.37 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Sqz Biotechnologies Co (SQZ)
| -93.1 | -36.3 | -90.8 | -98.3 | -- | -- | -- |
|
BSE Sensex*
| -10.1 | -2.5 | 2.0 | -5.0 | 5.2 | 5.7 | 10.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
|---|---|---|
|
Sqz Biotechnologies Co (SQZ)
| -91.7 | -69.2 |
|
S&P Small-Cap 600
| -17.4 | 25.3 |
|
BSE Sensex
| 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Sqz Biotechnologies Co (SQZ)
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen... Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts. Read more
-
Interim CEO & Director
Dr. Howard Bernstein M.D., Ph.D.
-
Gen. Counsel
Mr. Lawrence J. Knopf
-
Headquarters
Watertown, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Sqz Biotechnologies Co (SQZ)
What is the current share price of Sqz Biotechnologies Co (SQZ) Today?
The share price of Sqz Biotechnologies Co (SQZ) is $0.05 (NYSE) as of 01-Sep-2023 09:30 EDT. Sqz Biotechnologies Co (SQZ) has given a return of -98.31% in the last 1 years.
What is the current PB & PE ratio of Sqz Biotechnologies Co (SQZ)?
Since, TTM earnings of Sqz Biotechnologies Co (SQZ) is negative, P/E ratio is not available.
The P/B ratio of Sqz Biotechnologies Co (SQZ) is 0.50 times as on 01-Sep-2023, a 90 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2022 |
-- |
-- |
2021 |
-- |
-- |
2020 |
-- |
-- |
2019 |
-- |
-- |
2018 |
-- |
-- |
What is the 52 Week High and Low of Sqz Biotechnologies Co (SQZ)?
The 52-week high and low of Sqz Biotechnologies Co (SQZ) are Rs -- and Rs -- as of 04-Sep-2026.
What is the market cap of Sqz Biotechnologies Co (SQZ)?
Sqz Biotechnologies Co (SQZ) has a market capitalisation of $ 13 Mln as on 01-Sep-2023. As per SEBI classification, it is a Small Cap company.
Should I invest in Sqz Biotechnologies Co (SQZ)?
Before investing in Sqz Biotechnologies Co (SQZ), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.